NeoImmuneTech

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company founded in 2014 in Rockville, Maryland, with additional operations in Seongnam-si, Gyeonggi-do, South Korea. The company is dedicated to advancing the field of immuno-oncology and infectious disease through T cell-based therapeutics. Its core technology platform, NT-I7 (efineptakin alfa), is a unique T cell amplifier that enhances T cell numbers and immunological functions to improve the body's ability to eliminate cancer cells and infected cells. In addition to NT-I7, NeoImmuneTech is advancing a pipeline including NEOBASE (a Heterodimer Fc platform for multispecific antibodies), NT2020 (a T cell activator based on PROTAC platform technology), NT3020 (a T cell engager biologic), and NT5010 (an eTreg depletory that selectively eliminates effector Treg cells). The company pursues combination therapy strategies and partners with institutions globally across diverse disease areas.